A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 3537-3537 ◽  
Author(s):  
M. N. Saleh ◽  
I. Percent ◽  
T. E. Wood ◽  
J. Posey ◽  
J. Shah ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Death Receptor ◽  
Advanced Solid Tumors ◽  
Death Receptor 5 ◽  
Humanized Monoclonal Antibody ◽  
Antibody Targeting

scholarly journals Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors

2017 ◽  
Vol 17 (1) ◽  
pp. 215-221 ◽  
Author(s):  
Elaine T. Lam ◽  
S. Gail Eckhardt ◽  
Wells Messersmith ◽  
Antonio Jimeno ◽  
Cindy L. O'Bryant ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Humanized Monoclonal Antibody ◽  
Antibody Targeting

scholarly journals Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

2010 ◽  
Vol 25 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Andres Forero-Torres ◽  
Jatin Shah ◽  
Tina Wood ◽  
James Posey ◽  
Ronda Carlisle ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Phase I Trial ◽  
Death Receptor ◽  
Death Receptor 5 ◽  
Humanized Monoclonal Antibody ◽  
Antibody Targeting

scholarly journals A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors

2019 ◽  
Vol 37 (5) ◽  
pp. 1061-1074 ◽  
Author(s):  
Toshihiko Doi ◽  
Takeshi Aramaki ◽  
Hirofumi Yasui ◽  
Kei Muro ◽  
Masafumi Ikeda ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Japanese Patients ◽  
Humanized Monoclonal Antibody ◽  
Antibody Targeting
Sign in / Sign up

Export Citation Format

Share Document